Spectrum Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Spectrum Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Spectrum Pharmaceuticals Inc Strategy Report
- Understand Spectrum Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Spectrum Pharmaceuticals Inc (Spectrum) is a biopharma company that acquires, develops, and commercializes novel drug candidates for treatment of cancer. The company’s pipeline products include ROLONTIS, for treatment of chemotherapy-induced neutropenia helps to reduce the frequency of multiplication of tumors. Poziotinib, an irreversible tyrosine kinase inhibitor, for non-small cell lung cancer (NSCLC) tumors with various mutations. This product is in phase 2 trials and lead candidate for the organization. The company has R&D facilities in, Massachusetts and California, the US. The company operates in the US, Europe, Japan, and other countries. Spectrum is headquartered in Henderson, Nevada, the US.
Headquarters
United States of America
Address
11500 S Eastern Ave Ste 240, Henderson, Nevada, 89052-5576
Website
www.sppirx.com
Telephone
1 702 8356300
No of Employees
86
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$10.1M
Spectrum Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline - | Rolontis |
| Rolontis (eflapegrastim)- For chemotherapy-induced neutropenia | Spectrum Pharmaceuticals, Inc |
| Poziotinib- For solid tumors, EGFR mutations and NSCLC | Redefining cancer care |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In February, the company’s ROLVEDON injection received permanent J-code from U.S. Centers for Medicare and Medicaid services. |
| 2022 | Others | In December, the company’s ROLVEDON injection was added to NCCN Supportive Care Guidelines in Oncology. |
| 2022 | New Products/Services | In October, the company announced the availability of ROLVEDON (eflapegrastim-xnst) injection. |
Competitor Comparison
| Key Parameters | Spectrum Pharmaceuticals Inc | Pfizer Inc | AstraZeneca Plc | UroGen Pharma Ltd | Aeterna Zentaris Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Israel | Canada |
| City | Henderson | New York | Cambridge | Ra'Anana | Summerville |
| State/Province | Nevada | New York | England | Sharon (Netanya) | New Brunswick |
| No. of Employees | 86 | 88,000 | 89,900 | 198 | 21 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William L. Ashton | Chairman | Executive Board | 2019 | - |
| Tom Riga | Chief Executive Officer; Director; President | Executive Board | 2021 | - |
| Nora E. Brennan | Chief Financial Officer; Director | Executive Board | 2022 | - |
| Keith M. McGahan | Chief Legal Officer; Corporate Secretary; Executive Vice President | Senior Management | 2018 | - |
| Shanta Chawla | Vice President - Clinical Development | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward